Finding a way to catch multiple myeloma early; Guardant CEOs' vision for cancer detection

Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Join STAT in Boston on May 3 to take an inside look at the drug development process, with experts who've made that journey. Grab your ticket here. STAT+: Multiple myeloma is usually detected late. Some researchers think a precursor could help catch it early By Angus Chen National Cancer Institute/NIH Some scientists are focusing on an antibody anomaly as possible means for early detection of blood cancers. Others are skeptical. Read More STAT+: With milestones on the horizon, Guardant Health CEOs lay out their vision for cancer detection By Jonathan Wosen Guardant Health "It’s really going to be a defining moment for these liquid biopsy tests," Talasaz said of the readout of a pivotal trial of the SHIELD test. Read More STAT+: Nkarta studies of engineered natural killer cells show complete remissions in patients with blood cancers By Adam Feuerstein NIAID Nkrarta is among companies developing cell therapies for cancer based on NK cells, the body’s first line of defense against foreign invaders. Read More Sponsor content by STAT Events May 24 | The STAT Health Tech Summit oin us virtually, or in San Francisco, as we convene experts from Amazon Lab126, Ascension, Google Health, and more to discuss the next big innovations in health tech. We'll cover everything from patient data to AI to telemedicine. Learn more at statnews.com/summit. STAT+: Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review By Ed Silverman Adobe Sen. Elizabeth Warren is urging the Biden administration to use a controversial provision of federal law to widen access to a cancer drug. Read More STAT+: What Regeneron's purchase of Checkmate Pharma says about the state of biotech By Adam Feuerstein Erica Yoon for STAT There are a few angles through which to view the acquisition, and some of them are a reminder of how a bear market has affected the industry. Read More Opinion: STAT+: Pharma's role in value-based care starts with value-based research By Scott Swain and Kristin M. Zimmerman Savill and Bruce Feinberg Adobe A value-based care model cannot be generated from traditional trials alone. Something new — value-based research — is needed. Read More Tuesday, April 26, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser